Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.
UCL

University College London

Institute for Liver and Digestive Health,
UCL and Royal Free Hospital School of Medicine
Rowland Hill Street
London, NW3 2PF
UNITED KINGDOM
Visit website

Team Leader

Prof. Dr. Rajeshwar Mookerjee

Professor of Translational Hepatology
Phone: +44 207 433 2853
Send message

Team Staff

Dr. Jane Macnaughtan

Senior Lecturer
Phone: +44 207 433 2874
Send message

Institute Presentation

The Institute for Liver and Digestive Health (ILDH) at UCL is part of UCL’s Division of Medicine and is based in the Royal Free Hospital Campus of the allied medical school. It is embedded in the core of the translational activity of the Hepatology, Liver Transplantation, and Pancreatico-biliary clinical service. The Hepatology service at The Royal Free is a tertiary, high volume, referral centre for complex Hepatology and Liver Transplantation in London, with a substantive infrastructure for delivery of clinical research trials, including dedicated hepatology-specialised research nurses, data managers, and clinical fellows. It is partnered as the clinical site delivering studies for its parent academic institution, UCL, which currently holds 4 other active Horizon 2020 programmes, for 2 of which (CARBALIVE and ALIVER), it is the coordinating centre. and for one (LIVERHOPE) a participating centre. Within ILDH at UCL, the Liver Failure Group has played a key role in the journey of characterizing Acute-on-Chronic Liver Failure and strives to understand mechanistic drivers and new targets for therapy for this syndrome, as part of its broader portfolio of research activity.

UCL will contribute to the activities of the DECISION study through the following:

  • WP4: Delivering a clinical study of the Combinatorial therapies derived from earlier work packages, through its established research infrastructure and large clinical patient cohort. This includes: (a) helping develop and lock down an appropriate study protocol; (b) ensuring adherence to this protocol and delivery of a high-quality pilot trial to determine the safety and the efficacy of the combinatorial therapy; and (c) validating the companion biomarker used as a tool to identify patients who are likely to respond to the selected combinatorial therapy.
  • WP7: Dissemination and exploitation of the study outputs, specifically the incorporation into (inter)national guidelines. Raj Mookerjee is part of the EASL Cirrhosis Decompensation Guidelines Committee and also on several UK National Special Interest Groups, in addition to the steering committee of EFCLIF, and is thereby well-placed to support this activity.